Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results
Article in Blood Cancer Journal (April 2022)
The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)
Article in Haematologica (April 2021)
The power of proteasome inhibition in multiple myeloma
Article in Expert Review of Proteomics (November 2018)